Ursoliv, 250 mg capsules 100 pcs

Ursoliv – Hepatoprotector.

The active component is ursodeoxycholic acid.

The medicine has cholitholytic, choleretic, hypocholesterolemic, hypolipidemic and immunostimulatory effects.

Researches have shown that the active substance reduces hepatotoxicity of bile acids salts and has a pronounced protective effect on liver cells.

The drug Ursoliv reduces cholesterol levels by reducing its adsorption in the intestinal lumen.

The drug is able to destroy cholesterol-containing stones in the gallbladder.

The active substance stimulates the formation and excretion of bile, as well as the excretion of toxic acids through the intestinal lumen.

Ursodeoxycholic acid increases the secretion of gastric and pancreatic juices, increases lipase activity and has hypolipidemic effect.

An immunomodulatory effect is achieved by reducing the number of eosinophils, suppressing interleukin production and reducing antigen expression.

Indications

• Biliary stone disease
• Biliary reflux gastritis.
• Primary biliary cirrhosis in the absence of decompensation signs (symptomatic therapy);
• Dissolution of small and medium cholesterol stones with functioning gallbladder;

.

Active ingredient

Ursodeoxycholic acid

Composition

Active substance:

Ursodeoxycholic acid 250 mg.

Auxiliary substances:

Lactulose,

Microcrystalline cellulose,

povidone low molecular weight,

magnesium stearate,

talc.

How to take, the dosage

The drug is prescribed orally.

When dissolving cholesterol gallstones, the capsules are taken in the evening, before going to bed, without chewing and with a small amount of liquid.

Dose of 10 mg/kg of body weight which corresponds to: 2 capsules of Ursolive in patients with body weight less than 60 kg; 3 capsules in patients with body weight less than 80 kg; 4 capsules in patients with body weight less than 100 kg; 5 capsules in patients with body weight over 100 kg. The duration of treatment is 6-12 months.

In order to prevent recurrence of stone formation it is recommended to take the drug for several more months after the dissolution of stones.

In symptomatic treatment of primary biliary cirrhosis, the daily dose depends on the body weight and is from 2 to 6 capsules (10 to 15 mg/kg of body weight).

The drug is taken with food, with plenty of water.

To treat biliary reflux gastritis, 1 capsule 1 time per day before going to bed. The course of treatment is from 10-14 days to 6 months, if necessary – up to 2 years.

Interaction

When co-administered, antacids containing aluminum and ion exchange resins (colestyramine) reduce absorption of UDCA.

In concomitant use, hypolipidemic drugs (especially clofibrate), estrogens, neomycin or progestogens (oral contraceptives) increase bile cholesterol saturation and may decrease the ability of ursodeoxycholic acid to dissolve cholesterol gallstones.

Concomitant use of UDCA may increase absorption of cyclosporine.

Special Instructions

To dissolve UDCA gallstones, the concrements must be cholesterol-containing (not X-ray-contrasting), not more than 15-20 mm in size. At the same time the gallbladder must remain functional, and patency of the vesicular and common bile ducts must be preserved.

When administered to dissolve gallstones, it is necessary to perform monthly, and then – every 3 months – biochemical blood tests to determine the activity of liver transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase, and bilirubin concentration.

In case of preservation of elevated parameters the preparation should be discontinued.
In order to control treatment efficiency it is recommended to take radiologic and ultrasound investigation of biliary tracts each 6 months.

In case of gallstones calcification, impaired gallbladder contractility or frequent biliary colic attacks the treatment should be discontinued.

If within 6-12 months after the beginning of therapy partial dissolution of the concrements has not occurred, it is unlikely that the treatment will be effective.

The detection of an invisible gallbladder during treatment is an indication that complete dissolution of the concrements has not occurred, and treatment should be discontinued.

After complete dissolution of the stones, to exclude recurrence, it is recommended to continue the use of ursodeoxycholic acid, for 3 months.

The drug has no adverse effect on the ability to drive vehicles, and/or other mechanisms.

Contraindications

• acute cholecystitis
• liver cirrhosis
• severe renal and/or liver dysfunction.

.

Side effects

Allergic reactions.

Pregnancy use

Contraindicated.

Similarities

Ursofalc, Ursosan, Urdoxa, Exchol, Ursodez, Grinterol, Urcevelle, Ursodeoxycholic acid